Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 9, Art. 13 (pp. 124-132)    |    apr 2008       

»

Effectiveness of deltaran at chronic cerebral ischemia

Antipenko E.A., Gustov A.V., Chvatova E.M.

Brief summary

The choice of the treatment at chronic cerebral ischemia (CCI) is a problem due to various genesis of this pathology, the combination of the brain atrophy and cerebrovascular insufficiency, the present of concomitant diseases, differences of adaptive abilities at the different stages of CCI, individual capacities of human response. The arm of our study was to investigate the effectiveness of deltaran at CCI. Deltaran is known as neuropeptide with regulate action. Deltaran improves the effectiveness of the treatment for all stages of CCI.Deltaran significantly. Deltaran decreases the headache, vertigo and ataxia and sleep disorders. Deltaran has the nootropic action, especially for the 3 stage of CCI. Deltaran has regular anxiety and antidepressive effect, that confirm its adaptogene effect.


Key words

Chronic cerebral ischemia, adaptation, deltaran

Reference list

1. Voloshin, P.V. Lechenie sosydistih zabolevanii golovnogo i spinnogo mozga / P.V. Voloshin, V.I. Taiclin.- 3-e izd., dop.- M.:MEDpress-inform, 2005.- 688s.


2. Gannyshkina, I.V. Korrekciya cerebralnoi ishemii y nizkorezistentnih k nei jivotnih antistressornim preparatom «Deltaran» / I.V. Gannyshkina, I.L. Konorova, E.V. Koplik, A.L. Antelava // Bulleten eksperimentalnoi biologii i medicini.- 2006.- T.141,№3.- s.259-262.)


3. Gysev, E.I, Lekarstvennie sredstva v nevrologii. Prakticheskoe rykovodstvo / E.I. Gysev, N.A. Drobishev, A.S. Nikiforov.- M.: «Nolidj», 1998.- 304 s.


4. Gysev,E. Ishemiya golovnogo mozga. / E.I.Gysev, V.I. Skvorcova.- M.: Medicina; 2002.- 400 s.


5. Kadikov,A. Hronicheskaya nedostatochnost mozgovogo krovoobrasheniya (discirkylyatornaya encefalopatiya)/ A.S. Kadikov, L.S. Manvelov, N.V. Shahparonova.- SPb:GEOTAR-Media, 2006.- 236 s.)


6. Konorova, I.L Profilaktika preparatom «Deltaran» negativnih posledstvii perenesennogo emocionalnogo stressa pri posledyushei cerebralnoi ishemii y nizkorezistentnih jivotnih / I.L. Konorova, I.V. Gannyshkina, E.V. Koplik, A.L.Antelava // Bulleten eksperimentalnoi biologii i medicini.-2006.- T.141, №5.- s.499-502.)


7. Maklecova, M.G. Vliyanie delta-sonindyciryushego peptida na biosintez makromolekyl v tkanyah golovnogo mozga grizynov, podvergnytih stressy / M.G. Maklecova, I.I. Mihaleva, I.A. Prydchenko, G.T. Rihireva // Bulleten eksperimentalnoi biologii i medicini.- 2006.- T.141, №4.-s.400-403.


8. Syslina, Z. Sosydistie zabolevaniya golovnogo mozga: Epidemiologiya. Osnovi profilaktiki. /Z.A. Syslina, U.Ya. Varakin, N.V. Vereshagin //M.: MEDpress-inform. - 2006. – 256 s.


9. Troshin, V.D. Sosydistie zabolevaniya nervnoi sistemi: Rykovodstvo. / V.D.Troshin, A.V.Gystov, A.A.Smirnov // N.Novgorod: Izd-vo Nijegorodskoi gosydarstvennoi medicinskoi akademii.- 2006.- 538 s.


10. OBrien, J Vascular cognitive impairment /J. O’Brien, T. Erkinjuntti, B. Reisberg // Lancet Neurology. 2003: 2: 89-98.


11. OBrien, J. Cerebrovascular disease, cognitive impairment and dementia. / J. O’Brien // London. Martin Dunitz. 2004. 180 P.


12. Nicholson C.D. Pharmacology of nootropics and metabolicallyactive compounds in relation to their use in dementia. Psychopharmacology (Berlin) 1990; 101:147-159.